Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.
ANKTIVA, also called N-803 or nogapendekin alfa inbakicept, is a medicine used together with BCG therapy to treat a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This cancer is found only in the inner lining of the bladder and has not grown into the muscle layer. BCG (bacillus Calmette-Guérin) is a common immunotherapy that uses weakened bacteria to stimulate the immune system to attack cancer cells in the bladder. ANKTIVA helps boost this immune response, making the treatment more effective, especially when BCG alone has not worked well enough.
For patients whose bladder cancer does not improve after BCG treatment, treatment options have traditionally been limited and often involved surgery to remove the bladder (cystectomy). ANKTIVA Plus BCG offers a newer option that can help many patients clear their cancer and avoid surgery. Clinical studies have shown promising results, with many patients experiencing complete cancer clearance and lasting effects for months or years. Most patients tolerate this treatment well, with side effects usually mild to moderate, such as bladder irritation or discomfort. It is an important option for patients and doctors seeking to manage BCG-unresponsive NMIBC with less invasive methods.
If you or a loved one is facing bladder cancer that has not responded to BCG, you might hear about ANKTIVA Plus BCG during discussions about treatment options. Your care team may explain that this treatment is given directly into the bladder through a catheter, typically once a week for six weeks. It aims to boost the immune system’s ability to fight cancer cells more effectively than BCG alone. You may see this term in your treatment plan, clinical notes, or educational materials. Side effects are usually mild and may include bladder irritation or discomfort.
ANKTIVA (N-803) Plus BCG may appear in your medical records, treatment plans, or discussions about clinical trials. It might also be mentioned in drug information sheets or educational materials provided by your healthcare team. Sometimes it is referred to by other names such as N-803 or nogapendekin alfa inbakicept, so comparing terms can help avoid confusion.
Hearing about ANKTIVA Plus BCG does not mean your cancer is cured or that surgery will definitely be avoided. It is an option to try when BCG alone has not worked, but it does not guarantee success. It is also not an experimental or unproven treatment—it has been approved by the U.S. Food and Drug Administration (FDA) for certain patients—but it may not be suitable for everyone. Ongoing monitoring is needed to check how well the treatment is working and to watch for any return or progression of cancer.
If ANKTIVA Plus BCG is mentioned as a treatment option, it is important to ask your healthcare team about how it fits your specific situation. Questions might include how the treatment is given, what side effects to expect, how success will be measured, and what other options exist if this treatment does not work. Understanding the goals and possible outcomes can help you make informed decisions about your care.
This information is educational and does not replace medical advice. Treatment decisions depend on many factors unique to each person. Always discuss your diagnosis, treatment options, and any concerns with your oncology team to find the safest and most appropriate care for you.